MedTrace Logo

Multicenter Trial for Adults With Partial Seizures

NCT00034814 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2011-03-17

No results posted yet for this study

Summary

To compare seizure frequency in patients with refactory partial seizures (with or without generalization) who are taking Talampanel versus placebo as an add-on therapy to other licensed concomitant antiepileptic drugs (AEDs) and to determine the safety of Talampanel in this group of patients.

Conditions

Interventions

DRUG

Talampanel

Non-enzyme-inducing TLP 35mg TID

DRUG

Placebo

Enzyme-inducing placebo TID

DRUG

Talampanel

Enzyme-inducing Talampanel 35 mg TID

DRUG

Talampanel

Enzyme-inducing TLP 50mg TID

DRUG

Placebo

Non-enzyme-inducing placebo TID

DRUG

Talampanel

Non-enzyme-inducing TLP 25mg TID

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Primary Completion
2006-01-31
Completion
2006-01-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00034814 on ClinicalTrials.gov